Who Paid My Doc
Amy Schmidt
Hematology & Oncology Denver, CO Medical Doctor
NPI 1053509109 CMS profile 1292398
1719 E 19Th Ave, Denver, CO 80218
General payments
$2,773,305
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Amy Schmidt of Denver, CO is reported in the CMS Open Payments database as having received $2,773,305 across 409 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 99th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $69 | 2 | |
| 2022 | General | $968,949 | 126 | |
| 2021 | General | $984,750 | 110 | |
| 2020 | General | $513,463 | 109 | |
| 2019 | General | $306,075 | 62 |
Beside peers
- Amy Schmidt
- Hematology & Oncology median
- Middle half of Hematology & Oncology
- National median
In program year 2025, general payments to Amy Schmidt were reported at $69. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.
Show as a table
| Year | Amy Schmidt | Hematology & Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $306,075 | $529 | $121–$2,516 | $163 |
| 2020 | $513,463 | $339 | $82–$2,213 | $114 |
| 2021 | $984,750 | $263 | $49–$1,965 | $132 |
| 2022 | $968,949 | $416 | $103–$2,395 | $149 |
| 2023 | $0 | $542 | $125–$2,646 | $160 |
| 2024 | $0 | $692 | $141–$3,008 | $164 |
| 2025 | $69 | $683 | $143–$3,154 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 2 billing codesPaid by Medicare
$3,290
Medicare patients
61
Services billed
86
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 59% | |
| Chronic kidney disease | 39% | |
| Depression | 38% | |
| Heart failure | 34% | |
| Ischemic heart disease | 34% | |
| Diabetes | 30% | |
| Osteoporosis | 26% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
409 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Hematology & Oncology in Colorado
Yousuf Gaffar
Hematology & Oncology · Denver, CO
John Burke
Hematology & Oncology · Aurora, CO
Manojkumar Bupathi
Hematology & Oncology · Littleton, CO
Steven Schuster
Hematology & Oncology · Fort Collins, CO
Douglas Reznick
Hematology & Oncology · Aurora, CO
Daniel Pollyea
Hematology & Oncology · Aurora, CO
Related records
Hematology & Oncology in Colorado
Practitioners in the same specialty and state, ranked by reported value.
All Hematology & Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Colorado
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.